

Alicante, 25th November 2022

COMMUNICATION – MARKET NOTICE – FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.2.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "FacePhi" or "the Company") hereby notifies the following:

On November the 11th 2022, the Company published the resolution adopted by the Board about to produce a fourth issuance of 48,076,923 equity warrants convertible into Company' shares for a maximum conversion amount of 2,500,000 euros, the "Equity Warrants NOVEMBER 2022", with Nice & Green being the sole recipient of the issue of the Equity Warrants (NOVEMBER 2022).

Nice&Green, on November the 22nd of 2022, under the provisions of the investment agreement, notified to the Company and exercised its right to convert 260.811 Equity Warrants (NOVEMBER 2022) for a conversion amount of 500,000 euros.

As a result of the foregoing, the Company will be obliged to grant a capital increase title deed to attend those Equity warrants converted. There will be an issue of 210.811 new shares, with an issuing price of 1,9171 euros (issue premium 1,8771 euros plus 0.04 euros of nominal value)

Once the aforementioned capital increase deed has been granted, the share capital will be SIX HUNDRED EIGHTY-SEVEN THOUSAND FIVE HUNDRED AND TWO EUROS AND FORTY-EIGHT CENTS (€ 687.502,48), represented by SEVENTEEN MILLION ONE HUNDRED AND EIGHTY-SEVEN THOUSAND FIVE HUNDRED AND SIXTY-TWO (17.187.562) numbered from 1 to 17.187.562, shares of FOUR CENTS OF EURO (€0.04) nominal value each, of the same class, equal, cumulative and indivisible.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró
Chairman of the Board of Directors